Araim Pharmaceuticals (United States)
- Research works
- 28 ▼ 60% vs 2013–17
- Citations
- 767 27.3 per fractional work
- Top-10% rate
- 0.0% record average 16.5%
- Open access
- 57% world 28%
Not ranked overall: Araim Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which keywords describe research at Araim Pharmaceuticals (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Neuroprotection, Anemia, Cardiovascular Disease, Chronic Kidney Disease, Cancer Treatment, Heart Failure, Erythropoiesis-Stimulating Agents and Hypoxia-Inducible Factors.
- TARGET2 Balances
- Cancer
- PARP Inhibitors
- Central Sensitization
- BRCA Mutation
- Epidemiology
- Biomarkers
- Piezo1
- Oxidative Stress
- Hypoxia-Inducible Factors
- Heart Failure
- Cancer Treatment
- Anemia
- Neuroprotection
- Cardiovascular Disease
- Chronic Kidney Disease
- Erythropoiesis-Stimulating Agents
- Inflammation
- Apoptosis
- Piezo2
- Education
- Cell Death
- Cancer Therapy
- Neuroinflammation
- Applications
- ECB's Rescue Facility
- Technology
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 27 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 27 words, with their numbers
- Neuroprotection6▲ 58×5 topics
- Anemia6▲ 174×3 topics
- Cardiovascular Disease5▲ 17×2 topics
- Cancer Treatment5▲ 70×2 topics
- Chronic Kidney Disease5▲ 74×2 topics
- Heart Failure5▲ 40×2 topics
- Erythropoiesis-Stimulating Agents5▲ 1209×1 topic
- Hypoxia-Inducible Factors5▲ 1209×1 topic
- Inflammation2▲ 3.5×11 topics
- Oxidative Stress2▲ 3.9×8 topics
- Apoptosis2▲ 15×3 topics
- Piezo12▲ 120×1 topic
- Piezo22▲ 120×1 topic
- Biomarkers1▲ 7.8×4 topics
- Education1▲ 3.6×2 topics
- Epidemiology1◆ 1.13×9 topics
- Cell Death1▲ 20×2 topics
- BRCA Mutation1▲ 228×1 topic
- Cancer Therapy1▲ 6.3×2 topics
- Central Sensitization1▲ 54×2 topics
- Neuroinflammation1▲ 15×2 topics
- PARP Inhibitors1▲ 228×1 topic
- Applications1▲ 17×1 topic
- Cancer1▲ 2.5×3 topics
- ECB's Rescue Facility1▲ 332×1 topic
- TARGET2 Balances1▲ 332×1 topic
- Technology1▲ 8.2×1 topic
Which research topics does Araim Pharmaceuticals (United States) publish most on?
By volume in 2022–2025: GDF15 and Related Biomarkers, Erythropoietin and Anemia Treatment, Nutrition and Health in Aging and Medicinal Plants and Bioactive Compounds.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 GDF15 and Related Biomarkers Rheumatology 0 works
- 2 Erythropoietin and Anemia Treatment Hematology 0 works
- 3 Nutrition and Health in Aging Physiology 0 works
- 4 Medicinal Plants and Bioactive Compounds Molecular Biology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Araim Pharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 60% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Tarrytown
- Regeneron (United States)
- Mental Health Association of Westchester County
- Psychogenics (United States)
- Progenics Pharmaceuticals (United States)
- Restorix Health
- ARMGO Pharma (United States)
- Stone Barns Center for Food & Agriculture
- Historic Hudson Valley
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.